



Diagnostica Senese S.p.A.

www.diesse.it



PRESS RELEASE

DIESSSE LAUNCHES THE SARS-CoV-2 “NEUTRALIZING” Ab, AN IMPORTANT TEST FOR MEASURING VACCINE EFFECTIVENESS

Siena, 29 January 2021 – DIESSE Diagnostica Senese has released a new quantitative testing kit. The SARS-CoV-2 “Neutralizing” Ab, as anticipated in December, will be available on over 2000 Chorus platforms worldwide.

The test determines the quantity of neutralizing antibodies, capable of protecting us from the SARS-CoV-2 virus, found in serum samples.

Head of Biotechnology Research at Diesse, Alessandra Brogi, hopes that “the kit can be used *on a large scale to verify in a quantitative and standardised way whether or not patients who have either received the vaccine or have simply contracted COVID in the past, are in effect immune to the SARS-CoV-2 virus*”.

This new test adds to the range of Diesse kits currently available. The full range of serological and antigenic kits provide for COVID-19 testing during the different stages of the disease, and result in a complete diagnostic solution.

Diesse Diagnostica Senese S.p.A. is an Italian company which produces integrated and entirely in-house in-vitro diagnostic systems. Its headquarters are in Siena. Since its foundation in 1980, the company has developed, produced and marketed innovative diagnostic systems mainly in the field of immunodiagnosics and automatic ESR measurement.

The company has a global presence in over 100 countries, has 3 production sites and 1 research center, where the design and implementation of tests and new automated diagnostic detection tools meet Italian design and cutting-edge technology, identifying Diesse as an example of real “Diagnostics Evolution”.

Press Office:

Tatiana Zoppi – Diesse Diagnostica Senese

Tel.+39 348 3337827 – tatianazoppi@diesse.it